Susquehanna Fundamental Investments, LLC Prothena Corp Public LTD CO Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$24.75 - $40.66 $341,995 - $561,839	13,818 New	13,818 $342 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $86,173 - $207,657	3,425 New	3,425 $208,000
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $583,908 - $949,453	-19,290 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $457,314 - $795,603	-10,860 Reduced 36.02%	19,290 $953,000
Q2 2021 Aug 11, 2021	BUY	$21.63 - $57.65 $31,796 - $84,745	1,470 Added 5.13%	30,150 $1.55 Million
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $175,120 - $449,580	15,920 Added 124.76%	28,680 $720,000
Q4 2020 Feb 16, 2021	BUY	$10.12 - $13.94 $129,131 - $177,874	12,760 New	12,760 $153,000

183

42.8M

77.7K

92.7K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $791M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.